Your browser doesn't support javascript.
loading
Endogenous Bufadienolides, Fibrosis and Preeclampsia.
Reznik, Vitaliy A; Kashkin, Vladimir A; Agalakova, Natalia I; Adair, C David; Bagrov, Alexei Y.
Afiliação
  • Reznik VA; Department of Obstetrics and Gynecology, School of Pediatric Medicine, St. Petersburg 194353, Russia.
  • Kashkin VA; Valdman Institute of Pharmacology, Pavlov Medical University, St. Petersburg 197022, Russia.
  • Agalakova NI; Sechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, St. Petersburg 194223, Russia.
  • Adair CD; Sechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, St. Petersburg 194223, Russia.
  • Bagrov AY; Department of Obstetrics and Gynecology, University of Tennessee, Chattanooga, TN, USA.
Cardiol Res Pract ; 2019: 5019287, 2019.
Article em En | MEDLINE | ID: mdl-31915545
Frequency of preeclampsia has no tendency to decrease, and it still takes the leading position in the structure of maternal mortality and morbidity worldwide. In this review, we present the "fibrotic concept" of the etiology and pathogenesis of preeclampsia which involves system consisting of Na/K-ATPase and its endogenous ligands including marinobufagenin. New therapy of preeclampsia includes modulation of the Na/K-ATPase system by immunoneutralization of the marinobufagenin and use of mineralocorticoid antagonists which are capable to impair marinobufagenin-Na/K-ATPase interactions.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiol Res Pract Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cardiol Res Pract Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Estados Unidos